On May 14, 2025 Schrödinger, Inc. (Nasdaq: SDGR) reported that initial Phase 1 clinical data for SGR-1505, its investigational MALT1 inhibitor, will be presented at the European Hematology Association (EHA) (Free EHA Whitepaper) Annual Congress, taking place June 12 – 15, 2025, in Milan, Italy (Press release, Schrodinger, MAY 14, 2025, View Source [SID1234653100]). Additional data from this trial will be presented at the International Conference on Malignant Lymphoma, taking place June 17 – 21, 2025, in Lugano, Switzerland.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The Phase 1 study is designed to evaluate the safety, tolerability and anti-tumor activity of SGR-1505 in patients with relapsed/refractory B-cell malignancies. The poster presentations will include initial safety, pharmacokinetic and pharmacodynamic data, as well as preliminary efficacy data across a range of dosing levels, schedules and B cell malignancies. The data support the continued development of SGR-1505 in this patient population.
The abstract for the presentation at EHA (Free EHA Whitepaper) will be available online at www.ehaweb.org. Details of the data presentations are as follows:
European Hematology Association Annual Congress (EHA) (Free EHA Whitepaper)
Abstract Number: #PS1569
Poster Title: A Phase 1 study of SGR-1505, an oral, potent, MALT1 inhibitor for relapsed/refractory (R/R) B-cell malignancies, including chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL)
Presentation Date and Time: Saturday, June 14, 2025, 6:30-7:30PM CST (12:30-1:30PM ET)
Location: Poster Session 2
International Conference on Malignant Lymphoma (ICML)
Abstract Number: #444
Poster Title: A Phase 1 study of SGR-1505, an oral, potent MALT1 inhibitor for R/R B-cell malignancies, including chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Presentation Date and Time: Friday, June 20, 2025, 12:30-13:00PM CST (6:30-7:00AM ET)
Location: Marquee Parco Ciani
Webcast and Conference Call Information
Schrödinger will host a conference call to review and discuss the SGR-1505 Phase 1 data presented at EHA (Free EHA Whitepaper) on Thursday, June 12, 2025, at 8:00 a.m. ET. The live webcast can be accessed under "Events & Presentations" in the investors section of Schrödinger’s website, View Source To participate in the live call, please register for the call here. It is recommended that participants register at least 15 minutes in advance of the call. Once registered, participants will receive the dial-in information. The archived webcast will be available on Schrödinger’s website for approximately 90 days following the event.